Advances in Hematology / 2017 / Article / Tab 5

Research Article

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy

Table 5

Effect on the treatment group on being in the 100% chimerism on day 100 group versus being in the 86%–99% or <86% chimerism on day 100, adjusting for age and disease type.

VariableOR95% CI value

Treatment (versus BuCy)
 FluBu4 with kinetics0.730.17–3.11.672
 FluBu4 without Kinetics0.250.06–1.09.066
Age at transplant1.010.96–1.06.790
Disease1.530.57–4.13.403

Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; OR, odds ratio.